[1] |
JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui.
Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
|
[2] |
ZHANG Zan, ZHANG Hui, HE Songhua, LUO Yi.
Four exogenously-polluted components in Tianwang Buxin pills analyzed via TLC and UPLC-QQQ-MS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 156-162.
|
[3] |
JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling.
Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
|
[4] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[5] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[6] |
LIU Qian, HU Jing, LI Bo, YANG Xiaojing.
Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
|
[7] |
YIN Yuling, HU Chujuan, ZHANG Xiaomeng, WANG Yu, ZHANG Bing, LIN Zhijian.
Mining and validation of anti-adriamycin cardiotoxic effect of chicory extract
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 858-865.
|
[8] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[9] |
HE Xiong, MA Junlong, YANG Guoping.
Adverse events caused by HER2 conjugated antibodies via FAERS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 915-920.
|
[10] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[11] |
YU Yuehua, ZHAO Yan, LU Tiangong, SUN Zhenxiao.
Screening and in vitro study of traditional Chinese medicines against lung adenocarcinoma based on EGFR
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 735-741.
|
[12] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
[13] |
CHENG Fengjingming, LYU Jian, XIE Yanming.
Efficacy and safety of compound salvia miltiorrhiza spray/aerosol for angina pectoris due to coronary artery disease: a Meta analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 536-543.
|
[14] |
FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin.
Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
|
[15] |
HUANG Wei, WU Ruiqing, SUN Hua, SHI Jiangong, LIU Qian.
Reversal of multidrug resistance in human oral epithelial cancer cells KBV200 by a natural product
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 403-408.
|